The following announcement replaces the Director Dealing and Holding in the Company announcement released on 30 March 2023 at 15:00 under RNS Number 8252U. In the announcement it was stated that Dr Lyske had paid 106.7 pence per Ordinary Share, an amount that was inclusive of dealing costs; exclusive of dealing costs, a price of 105.0 pence per Ordinary Share was paid. Accordingly, the purchase price and the PDMR table in the announcement have been amended.  All other details remain unchanged.

TINTRA PLC

 ("Tintra", the "Group" or the "Company")

Director Dealing and Holding in the Company

The Company announces that Dr Joe Lyske, the Company's Chief Science Officer, has purchased a total of 47,207 ordinary shares of 1 pence each ("Ordinary Shares"). 

Following this purchase, Dr Lyske holds 108,002 Ordinary Shares (equivalent to 0.67% of the issued ordinary share capital).  In addition, he is a founder and person of significant control, but not a director, of Time Machine Capital 2 Limited, which holds 636,475 Ordinary Shares (equivalent to 3.94% of the issued ordinary share capital) and 636,475 warrants (full details as announced 24 November 2021).